BRPI0908887A2 - composição farmacêutica líquida, recipiente farmacêutico, métodos para preparar e para fabricar uma composição farmacêutica, e, uso de uma composição farmacêutica - Google Patents

composição farmacêutica líquida, recipiente farmacêutico, métodos para preparar e para fabricar uma composição farmacêutica, e, uso de uma composição farmacêutica

Info

Publication number
BRPI0908887A2
BRPI0908887A2 BRPI0908887A BRPI0908887A BRPI0908887A2 BR PI0908887 A2 BRPI0908887 A2 BR PI0908887A2 BR PI0908887 A BRPI0908887 A BR PI0908887A BR PI0908887 A BRPI0908887 A BR PI0908887A BR PI0908887 A2 BRPI0908887 A2 BR PI0908887A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition
pharmaceutical
preparing
manufacturing
Prior art date
Application number
BRPI0908887A
Other languages
English (en)
Inventor
Erich Kohler
Sascha Stolzenberger
Original Assignee
Biogenerix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenerix Ag filed Critical Biogenerix Ag
Publication of BRPI0908887A2 publication Critical patent/BRPI0908887A2/pt
Publication of BRPI0908887B1 publication Critical patent/BRPI0908887B1/pt
Publication of BRPI0908887B8 publication Critical patent/BRPI0908887B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0908887A 2008-02-08 2009-02-09 composição farmacêutica líquida, recipiente farmacêutico, e, métodos para preparar e para fabricar uma composição farmacêutica BRPI0908887B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08151231 2008-02-08
EP08151231.1 2008-02-08
PCT/EP2009/051451 WO2009098318A1 (en) 2008-02-08 2009-02-09 Liquid formulation of fsh

Publications (3)

Publication Number Publication Date
BRPI0908887A2 true BRPI0908887A2 (pt) 2015-09-15
BRPI0908887B1 BRPI0908887B1 (pt) 2021-01-19
BRPI0908887B8 BRPI0908887B8 (pt) 2021-05-25

Family

ID=40568186

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908887A BRPI0908887B8 (pt) 2008-02-08 2009-02-09 composição farmacêutica líquida, recipiente farmacêutico, e, métodos para preparar e para fabricar uma composição farmacêutica

Country Status (27)

Country Link
US (4) US20110054410A1 (pt)
EP (2) EP2412385A1 (pt)
JP (1) JP5620824B2 (pt)
KR (2) KR101662631B1 (pt)
CN (3) CN104688679A (pt)
AT (1) ATE523209T1 (pt)
AU (1) AU2009211331B2 (pt)
BR (1) BRPI0908887B8 (pt)
CA (2) CA2713386C (pt)
CY (1) CY1112082T1 (pt)
DE (1) DE202009009905U1 (pt)
DK (1) DK2249869T3 (pt)
EA (1) EA019530B1 (pt)
ES (1) ES2372470T3 (pt)
HK (1) HK1149494A1 (pt)
HR (1) HRP20110801T1 (pt)
IL (1) IL206759A (pt)
ME (1) ME01337B (pt)
MX (1) MX2010008802A (pt)
NZ (1) NZ586588A (pt)
PL (1) PL2249869T3 (pt)
PT (1) PT2249869E (pt)
RS (1) RS52106B (pt)
SI (1) SI2249869T1 (pt)
UA (1) UA99337C2 (pt)
WO (1) WO2009098318A1 (pt)
ZA (1) ZA201004457B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
CA2740685C (en) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081755A1 (es) 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014008872A2 (pt) * 2011-11-09 2017-04-18 Adisseo France Sas dieta antes do abate que inclui metionina e seu uso em métodos para melhorar a maciez de carne
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
CN105726468A (zh) * 2016-02-28 2016-07-06 中国农业科学院特产研究所 梅花鹿用超数排卵聚乙烯吡咯烷酮fsh复合缓释注射剂
US10085971B2 (en) * 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
US20230364172A1 (en) * 2022-05-14 2023-11-16 Syncotrance, LLC Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
CA2018676C (en) 1989-06-20 2003-05-06 Christie A. Kelton Novel heteropolymeric protein production methods
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4440587A1 (de) 1994-11-14 1996-05-15 Fliether Karl Gmbh & Co Basquill-Schloß
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
DK1775346T3 (da) 1997-06-25 2009-09-28 Merck Serono Sa Disulfid-tværbundne glycoproteinhormonanaloger, deres fremstilling og anvendelse
JP4719357B2 (ja) * 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
EP1169349B1 (en) 1999-04-16 2007-03-28 Instituto Massone S.A. Process for preparing gonadotropin compositions
WO2001058493A1 (en) 2000-02-11 2001-08-16 Maxygen Aps Conjugates of follicle stimulating hormones
DE10249817A1 (de) 2002-10-24 2004-05-13 Daimlerchrysler Ag Schaltanordnung zur Betätigung von Beleuchtungssystemen an einem Kraftfahrzeug
PL1610822T5 (pl) 2003-04-02 2019-05-31 Ares Trading Sa Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem
EP1697412B1 (en) 2003-12-22 2009-10-21 Ares Trading S.A. Method for purifying fsh
MX2007005327A (es) 2004-11-09 2007-08-02 Ares Trading Sa Metodo para purificacion de la hormona foliculo estimulante (hfe).
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
NZ581702A (en) 2007-06-28 2011-10-28 Biogenerix Ag Follicle stimulating hormone producing cell clone

Also Published As

Publication number Publication date
CA2926500A1 (en) 2009-08-13
KR101573773B1 (ko) 2015-12-02
CA2713386C (en) 2016-04-19
EA201070940A1 (ru) 2010-12-30
ZA201004457B (en) 2011-05-25
US20160303238A1 (en) 2016-10-20
CA2713386A1 (en) 2009-08-13
AU2009211331B2 (en) 2014-07-03
US20160303201A1 (en) 2016-10-20
RS52106B (en) 2012-08-31
IL206759A (en) 2015-02-26
US20160303202A1 (en) 2016-10-20
CN110433136A (zh) 2019-11-12
EP2412385A1 (en) 2012-02-01
HRP20110801T1 (hr) 2011-12-31
NZ586588A (en) 2012-10-26
CN101970010A (zh) 2011-02-09
CN104688679A (zh) 2015-06-10
DE202009009905U1 (de) 2009-10-29
EP2249869A1 (en) 2010-11-17
DK2249869T3 (da) 2011-12-12
BRPI0908887B8 (pt) 2021-05-25
MX2010008802A (es) 2011-03-29
BRPI0908887B1 (pt) 2021-01-19
JP2011514317A (ja) 2011-05-06
ATE523209T1 (de) 2011-09-15
ES2372470T3 (es) 2012-01-20
PT2249869E (pt) 2011-12-16
HK1149494A1 (en) 2011-10-07
PL2249869T3 (pl) 2012-02-29
KR20100123697A (ko) 2010-11-24
SI2249869T1 (sl) 2012-01-31
KR101662631B1 (ko) 2016-10-05
KR20150138428A (ko) 2015-12-09
CY1112082T1 (el) 2015-11-04
ME01337B (me) 2013-12-20
JP5620824B2 (ja) 2014-11-05
AU2009211331A1 (en) 2009-08-13
UA99337C2 (ru) 2012-08-10
IL206759A0 (en) 2010-12-30
WO2009098318A1 (en) 2009-08-13
US20110054410A1 (en) 2011-03-03
EA019530B1 (ru) 2014-04-30
EP2249869B1 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
BRPI0908887A2 (pt) composição farmacêutica líquida, recipiente farmacêutico, métodos para preparar e para fabricar uma composição farmacêutica, e, uso de uma composição farmacêutica
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
WO2006138181A3 (en) Self-buffering protein formulations
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
WO2007059979A3 (en) Allergy treatment by epicutaneous allergen administration
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
WO2011146808A3 (en) Topical formulation for a jak inhibitor
WO2009053741A3 (en) Novel formulation
BRPI0510449A (pt) uso de formulações de meloxicam em medicina veterinária
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
EA200601901A1 (ru) Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
NO20064196L (no) Utvortes preparat for behandling av smertefulle hudskader
WO2012071480A3 (en) Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2012083397A8 (en) Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
JP2017222676A5 (pt)
PE20141530A1 (es) Composicion farmaceutica para uso en inflamacion y dolor
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes
WO2005120486A3 (en) Novel use of cytotoxic drugs for treatment and prophylasxis of aging diseases by reversing the loss of elasticity of epithelial cells due to aging

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: BIOGENERIX GMBH (DE)

B25A Requested transfer of rights approved

Owner name: RATIOPHARM GMBH (DE)

B25A Requested transfer of rights approved

Owner name: THERAMEX HQ UK LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: THERAMEX HQ UK LIMITED (GB)